Ultragenyx Pharmaceutical Inc.RARENASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-54.56%
↓ 119% below average
Average (39q)
-24.93%
Historical baseline
Range
High:133.33%
Low:-448.65%
CAGR
+0.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -54.56% |
| Q2 2025 | 25.48% |
| Q1 2025 | -12.95% |
| Q4 2024 | 0.71% |
| Q3 2024 | 7.89% |
| Q2 2024 | 25.12% |
| Q1 2024 | -33.55% |
| Q4 2023 | 31.84% |
| Q3 2023 | 0.89% |
| Q2 2023 | 3.43% |
| Q1 2023 | -7.87% |
| Q4 2022 | 38.29% |
| Q3 2022 | -54.87% |
| Q2 2022 | -3.20% |
| Q1 2022 | -22.35% |
| Q4 2021 | -65.74% |
| Q3 2021 | 40.33% |
| Q2 2021 | 10.84% |
| Q1 2021 | -448.65% |
| Q4 2020 | 67.26% |
| Q3 2020 | -375.61% |
| Q2 2020 | 120.00% |
| Q1 2020 | -26.54% |
| Q4 2019 | 17.35% |
| Q3 2019 | -13.95% |
| Q2 2019 | 5.49% |
| Q1 2019 | -5.20% |
| Q4 2018 | 0.57% |
| Q3 2018 | -64.15% |
| Q2 2018 | -268.25% |
| Q1 2018 | 133.33% |
| Q4 2017 | -1.07% |
| Q3 2017 | -8.72% |
| Q2 2017 | -5.52% |
| Q1 2017 | 6.86% |
| Q4 2016 | -6.71% |
| Q3 2016 | -12.33% |
| Q2 2016 | -8.15% |
| Q1 2016 | 4.93% |
| Q4 2015 | -37.86% |